Publications by authors named "Atsushi Sato"

Genome editing (GE) technology holds significant promise for advancements in crop development and medical applications. However, public acceptance of GE in Japan remains uncertain. This study aimed to examine how knowledge impacts public acceptance of GE technology, focusing on differences across diffusion stages and application purposes.

View Article and Find Full Text PDF

Activation of the melanocortin 1 receptor (MC1R) mediates melanogenesis in melanocytes, anti-inflammatory effects in inflammatory cells, and antifibrotic effects in fibroblasts. Thus, MC1R agonists are expected to be beneficial for treating skin, autoimmune, inflammatory, and fibrotic diseases. Afamelanotide, an α-melanocyte-stimulating hormone (α-MSH) analogue MC1R agonist, is used clinically for treating erythropoietic protoporphyria (EPP) as a subcutaneous implant formulation.

View Article and Find Full Text PDF

Purpose: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework.

Patients And Methods: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups.

View Article and Find Full Text PDF

Neurological surgery requires techniques and equipment to magnify the delicate brain structures and blood vessels that are difficult to discern with the naked eye. The introduction of surgical microscopes in the 1960s marked a breakthrough leading to the development of microsurgery and significant improvements in the safety and efficacy of neurosurgery. Subsequently, minimally invasive neurosurgery became prevalent, particularly with advancements in endoscopic technology in the 1990s.

View Article and Find Full Text PDF
Article Synopsis
  • The ALL-R08 study in Japan focuses on children with first-relapsed acute lymphoblastic leukemia (ALL) to evaluate the effectiveness of the BFM-S classification and measurable residual disease (MRD) as prognostic tools for patient survival.
  • The study consists of two parts: an observational study (ALL-R08-I) and a clinical trial (ALL-R08-II) that differentiates treatment based on MRD levels after induction therapy.
  • Results showed varying 3-year event-free survival rates across different BFM-S groups, indicating that children treated with either Japanese or BFM-type protocols have similar outcomes for managing first-relapsed ALL.
View Article and Find Full Text PDF

Background: Tissue plasminogen activator (tPA) is an effective treatment for acute ischemic stroke. Although initial improvement is observed when administered for branch atheromatous disease (BAD), some cases subsequently worsen. Clinical data on the characteristics of these patients is lacking, and the benefits of tPA are unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Acute lymphoblastic leukemia (γδ T-ALL) is a rare and complex condition in children, prompting a study of 200 pediatric cases to identify its clinical and genetic characteristics.
  • The research revealed that very young children (under 3 years) with γδ T-ALL face a significantly high risk and display specific genetic changes, particularly involving STAG2 inactivation and LMO2 activation.
  • Importantly, their findings suggest that targeting DNA repair pathways linked to STAG2 inactivation with specific drugs could offer new treatment options and help classify patients based on their risk levels.
View Article and Find Full Text PDF

Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?".

Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019.

View Article and Find Full Text PDF

Introduction: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • G-CSF is a supportive treatment used to prevent severe complications from chemotherapy in patients with non-round cell soft tissue sarcomas (NRC-STS), with two key clinical questions raised about its effectiveness.
  • A literature review found a limited number of studies that addressed these questions, resulting in only a few articles being included for analysis.
  • The conclusion suggests that there is insufficient scientific evidence to confirm the benefits of G-CSF prophylaxis in improving treatment outcomes for NRC-STS, indicating the need for further research.
View Article and Find Full Text PDF

This nationwide study retrospectively examined the center effect on allogeneic hematopoietic stem cell transplantation (allo-HSCT) for adult B-cell acute lymphoblastic leukemia. The cohort analyses were separated into Philadelphia chromosome (Ph)-positive and -negative cases. The patients were divided into low- and high-volume groups according to the number of allo-HSCTs at each facility.

View Article and Find Full Text PDF
Article Synopsis
  • Relapsed or refractory acute myeloid leukemia (AML) has poor outcomes, and the impact of granulocyte colony-stimulating factor (G-CSF) combined with chemotherapy is still debated.
  • A systematic literature review and meta-analysis were conducted, assessing 11 studies, which suggested that G-CSF priming did not significantly improve response rates or overall survival for AML patients, although there was a slight trend towards lower relapse rates.
  • Certain groups, particularly those with intermediate cytogenetic risk and those receiving high-dose cytarabine, showed prolonged overall survival with G-CSF priming, indicating the need for further research to find the most suitable patients for this treatment approach.*
View Article and Find Full Text PDF

Background: Knee osteoarthritis (KOA) is a chronic joint disease affecting activities of daily living (ADL) and quality of life due to pain and limited range of motion, afflicting a large number of patients worldwide. However, it is difficult to prevent the progression of the disease. Therapeutic strategies for KOA aim to maintain ADL and QOL by alleviating pain or managing locomotive function.

View Article and Find Full Text PDF

Background: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question.

View Article and Find Full Text PDF

In a previous study, a novel human corneal-like epithelium model utilizing an immortalized human corneal epithelial cell line (iHCE-NY1) was developed as an alternative to animal models to identify chemicals not classified under the United Nations Globally Harmonized System of Classification and Labeling of Chemicals (GHS) and was evaluated following the criteria of Test Guideline 492 of the Organization for Economic Co-operation and Development (OECD). In the present study, our aim was to establish an eye irritation test protocol using the iHCE-NY1 model to classify liquid chemicals under the GHS ocular hazard categories: no effect, no classification (No Cat.), Category 2 (Cat.

View Article and Find Full Text PDF
Article Synopsis
  • Granulocyte colony-stimulating factor (G-CSF) is used to prevent febrile neutropenia (FN) in cancer patients, with two types available in Japan: long-lasting PEG G-CSF and short-term non-PEG G-CSF.
  • A systematic review of studies found that PEG G-CSF significantly reduces the incidence of FN compared to non-PEG G-CSF, based on a thorough analysis of 23 articles.
  • The study concludes that a single dose of PEG G-CSF is preferred for primary prevention of FN, as it shows stronger evidence compared to multiple doses of non-PEG G-CSF.
View Article and Find Full Text PDF

Objective: Preservation of visual function is important in surgery for suprasellar tumors. Visual evoked potentials (VEPs) are expected to play an important role in monitoring visual function during surgery. Given the lack of information in this field, the authors aimed to investigate the effects of optic nerve compression caused by suprasellar tumors to understand the possible usefulness of VEP monitoring using off-response (OFR) VEP.

View Article and Find Full Text PDF
Article Synopsis
  • Granulocyte colony-stimulating factor (G-CSF) is used to reduce the risk of neutropenia and infections during cancer chemotherapy, but its effectiveness for digestive system tumors is still uncertain.
  • A systematic review was conducted to evaluate the effectiveness of G-CSF as primary prophylaxis and its impact on the intensity of chemotherapy for various digestive system tumors.
  • The findings indicated that while G-CSF's use in colorectal cancer chemotherapy is inappropriate, there wasn't enough data to make strong recommendations for other types of digestive cancers.
View Article and Find Full Text PDF

Background: Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan.

Methods: In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy.

View Article and Find Full Text PDF

Sebaceous carcinoma of the breast is an extremely rare histological subtype of breast cancer, with fewer than 30 cases reported to date. Because of its extremely rare histological presentation, there are few case reports that highlight its cytological findings. In this case report, the cytomorphological features of a sebaceous carcinoma of the breast are described in detail.

View Article and Find Full Text PDF
Article Synopsis
  • The review examines the optimal timing for administering prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) during cancer chemotherapy, focusing mainly on Day 2 versus Days 3-5.
  • Out of 300 studies initially reviewed, only four met the criteria, suggesting a potential increase in febrile neutropenia when G-CSF is given on Days 3-5 compared to Day 2, but no significant differences in overall survival or infection-related mortality were found.
  • The findings indicate weak recommendations for both timing options and emphasize the need for more research to make clearer guidelines for pegylated G-CSF administration.
View Article and Find Full Text PDF

Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes.

View Article and Find Full Text PDF

Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes.

View Article and Find Full Text PDF

Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library.

View Article and Find Full Text PDF